Antares Pharma to Present at the Cowen and Company 34th Annual Healthcare Conference
February 26 2014 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
Wotton, Ph.D., President and Chief Executive Officer, will present
at the Cowen and Company 34th Annual Healthcare Conference on
Wednesday March 5, 2014 at 8:00 am Eastern Time.
A live webcast of the presentation will be available via the
“Investor Relations” page of the Antares website,
www.antarespharma.com. A replay of the webcast will also be
archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products. The Company has received marketing
approval from the U.S. Food and Drug Administration for OTREXUP™
(methotrexate) injection for the treatment of adults with severe
active rheumatoid arthritis, children with active polyarticular
juvenile idiopathic arthritis and adults with severe recalcitrant
psoriasis. Antares Pharma is also developing VIBEX® QS T for
testosterone replacement therapy. The Company's technology
platforms include VIBEX® disposable Medi-Jet, disposable multi-use
pen injectors and Vision™ reusable needle-free injectors marketed
as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva)
and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma
has a multi-product deal with Teva that includes Tev-Tropin®
[somatropin (rDNA origin) for injection] human growth hormone
(hGH), VIBEX® epinephrine and several other products. Antares
Pharma’s partnership with Ferring includes Zomacton® hGH
(somatropin) injection. In the U.S. Antares has received FDA
approval for Gelnique 3%™ (oxybutynin) gel, a treatment for
overactive bladder that is marketed by Actavis. Elestrin®
(estradiol gel) is FDA approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
and is marketed in the U.S. by Meda Pharma. Antares Pharma has two
facilities in the U.S. The Parenteral Products Group located in
Minneapolis, Minnesota directs the manufacturing and marketing of
the Company’s reusable needle-free injection devices and related
disposables, and develops its disposable pressure-assisted Medi-Jet
and pen injector systems. The Company’s corporate office and
Product Development and Commercial Groups are located in Ewing, New
Jersey.
Antares Pharma, Inc.Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024